## Contents

**Contents**

Preface

Contributors xi

Part I: PRINCIPLES OF SKIN AND FORMULATION INTERACTIONS

1 Practical Considerations for Topical Drug Formulations With and Without Enhancers 1
   Eugene R. Cooper and Dinesh C. Patel
      I. Introduction 1
      II. Vehicle Design 1
      III. Evaluation of Vehicle Performance 7
      IV. Formulation Example: Desonide 10
      References 11

2 The Importance of Epidermal Lipids for the Stratum Corneum Barrier 13
   Peter M. Elias
      I. Evolution of Current Concepts of Stratum Corneum Structure 13
      II. Epidermal Differentiation 15
      III. Composition of Stratum Corneum Lipids 17
      IV. Lipid Biosynthetic Gradients in the Epidermis 19
      V. Clinical and Pathophysiologic Implications of the Two-Compartment Model 24
      References 26
3 Stratum Corneum Structure and Transport Properties 29
Stig E. Friberg, Ibrahim H. Kayali, Marion Margosiak, David W. Osborne, and Anthony J. I. Ward
   I. Introduction 29
   II. Lipid Organization 29
   III. Summary 44
   References 44

4 Penetration Enhancer Incorporation in Bilayers 47
Anthony J. I. Ward and Regina Tallon
   I. Introduction 47
   II. Experimental Background 48
   III. Experimental 53
   IV. Results and Discussion 54
   References 66

5 The Influence of Skin Surface Lipids on Topical Formulations 69
David W. Osborne and Douglas A Hatzenbuhler
   I. Introduction 69
   II. Skin and Surface Lipid Excretion 70
   III. Composition of Skin Surface Lipids 73
   IV. Fallacies Concerning Skin Surface Lipids 77
   V. Model Skin Surface Lipids 78
   VI. Interactions Between Skin Surface Lipids and Topical Formulations 82
   VII. Concluding Remarks 83
   References 84

6 Immunology of the Skin 87
David H. Lynch and Lee K. Roberts
   I. Introduction 87
   II. Structure and Histological Organization of the Skin 88
   III. Inflammation and Immune Responses in the Skin 90
   IV. Skin-Associated Lymphoid Tissues 92
   V. Immunocompetent Cells Within the Skin 94
   VI. Effects of Agents that Deplete Skin of Langerhans Cells on Immune Responses to Antigens Encountered Through the Skin 101
   VII. Conclusion 102
   References 104
<table>
<thead>
<tr>
<th>Contents</th>
<th>vii</th>
</tr>
</thead>
<tbody>
<tr>
<td>Part II: DRUG FORMULATION SELECTION AND TESTING FOR TOPICAL USE</td>
<td></td>
</tr>
<tr>
<td>7 Computational Methods for Prodrug or Drug Analogue Selection Optimized for Percutaneous Delivery 109</td>
<td></td>
</tr>
<tr>
<td><strong>David W. Osborne</strong></td>
<td></td>
</tr>
<tr>
<td>I. Introduction</td>
<td>109</td>
</tr>
<tr>
<td>II. Description of the Models</td>
<td>110</td>
</tr>
<tr>
<td>III. Comparison of Predicted and Experimental Flux Values</td>
<td>112</td>
</tr>
<tr>
<td>IV. Use of the Predictive Models</td>
<td>112</td>
</tr>
<tr>
<td>V. Contour Plots</td>
<td>113</td>
</tr>
<tr>
<td>VI. Additional Considerations</td>
<td>124</td>
</tr>
<tr>
<td>References</td>
<td>125</td>
</tr>
<tr>
<td>8 Kinetic Considerations in the Design of Surfactant-Based Topical Formulations 127</td>
<td></td>
</tr>
<tr>
<td><strong>Anthony J. I. Ward</strong></td>
<td></td>
</tr>
<tr>
<td>I. Introduction</td>
<td>127</td>
</tr>
<tr>
<td>II. Experimental Background</td>
<td>128</td>
</tr>
<tr>
<td>III. Results and Discussion</td>
<td>129</td>
</tr>
<tr>
<td>IV. Summary</td>
<td>139</td>
</tr>
<tr>
<td>References</td>
<td>140</td>
</tr>
<tr>
<td>9 The Use of Phase Behavior and Laboratory Robotics for the Optimization of Pharmaceutical Topical Formulations 143</td>
<td></td>
</tr>
<tr>
<td><strong>David W. Osborne</strong></td>
<td></td>
</tr>
<tr>
<td>I. Introduction</td>
<td>143</td>
</tr>
<tr>
<td>II. Determination of Component Ranges</td>
<td>145</td>
</tr>
<tr>
<td>III. Optimization Techniques</td>
<td>188</td>
</tr>
<tr>
<td>IV. Closing Remarks</td>
<td>193</td>
</tr>
<tr>
<td>References</td>
<td>194</td>
</tr>
<tr>
<td>10 General Considerations for Stability Testing of Topical Pharmaceutical Formulations 197</td>
<td></td>
</tr>
<tr>
<td><strong>Gary R. Dukes</strong></td>
<td></td>
</tr>
<tr>
<td>I. Introduction</td>
<td>197</td>
</tr>
<tr>
<td>II. Preformulation Stage</td>
<td>199</td>
</tr>
<tr>
<td>III. Formulation Development Stage</td>
<td>201</td>
</tr>
<tr>
<td>IV. Proposed Product</td>
<td>206</td>
</tr>
<tr>
<td>V. New Product Stage</td>
<td>208</td>
</tr>
<tr>
<td>VI. Established Product Stage</td>
<td>208</td>
</tr>
<tr>
<td>VII. Product Revision Stage</td>
<td>209</td>
</tr>
<tr>
<td>VIII. Conclusion</td>
<td>210</td>
</tr>
<tr>
<td>References</td>
<td>210</td>
</tr>
</tbody>
</table>
11  In Vitro Testing of Topical Pharmaceutical Formulations
Ronald C. Wester and Howard I. Maibach

I. Introduction 213
II. Basic Study Design 213
III. Factors 214
IV. Conclusions 220

References 220

12 Drug Delivery from Topical Formulations: Theoretical
Prediction and Experimental Assessment
William J. Addicks, Gordon L. Flynn, Norman D. Weiner,
and Rane L. Curl

I. Introduction 221
II. In Vitro Release from Vehicles 222
III. Applications of Theory: In Vitro Release Studies 232
IV. Diffusion Studies Involving Skin 237

References 242

13 The Use of Solubility Parameters of Drug and Vehicle
to Describe Skin Transport
Kenneth B. Sloan

I. Introduction 245
II. General Applications of Regular Solution Theory
to Partitioning Processes 247
III. Application of Regular Solution Theory to
Percutaneous Absorption Processes 249
IV. Conclusion 268

References 269

14 Use of an Epidermal Culture for Cutaneous Toxicity
Studies
F. L. Vaughan

I. Introduction 271
II. Developing Cultivation Procedures 274
III. Stratification and Differentiation of Keratinocytes
Cultured on Nylon Membranes 282
IV. Experimentation with Sulfur Mustard in Cutaneous
Toxicity Studies Using the Epidermal Culture 286
V. Summary and Conclusions 295

References 296
Part III: NONTRADITIONAL TOPICAL DRUG DELIVERY FORMULATIONS

15 The Microsponge: A Novel Topical Programmable Delivery System
Sergio Nacht and Martin Katz

I. The Need for Better Skin Delivery Systems 299
II. Microsponge Technology 300
III. Microsponge Synthesis 301
IV. Physical Characterization of Microsponges 307
V. Programmable Parameters 308
VI. Release Mechanisms 310
VII. Safety Substantiation 312
VIII. Increased Efficacy and Aesthetic Appeal of Drug Formulations 317
IX. Possible Applications for Microsponge Systems 322
X. Advantages for Industry 324
References 324

16 Liposome-Based Vehicles for Topical Delivery
Paul S. Uster

I. Introduction 327
II. "Liposomology" 327
III. Formulating Topical Products with Liposomes 332
IV. Research Studies 337
V. Future Directions 344
References 346

17 Surfactant Association Colloids as Topical Drug Delivery Vehicles
David W. Osborne, Anthony J. I. Ward, and Kilian J. O'Neill

I. Introduction 349
II. Description of Surfactant Association Colloids 350
III. Formulation of Topical Surfactant Association Colloids 355
IV. Drug Delivery from Topical Surfactant Association Colloids 372
V. Concluding Remarks 376
References 377
18 Gel Dosage Forms: Theory, Formulation, and Processing

Lorraine E. Pena

I. Theory 381
II. Formulation 382
III. Processing 387
References 388

19 Using Silicones in Topical Products

Michael S. Starch

I. Introduction 389
II. Types of Silicones Used in Topical Products and Their Properties 390
III. Formulating Silicones into Conventional Topical Formulations 397
IV. Nontraditional Topical Formulations Based on Silicones 406
References 408